Zevalin and BEAM (Z‐BEAM) versus rituximab and BEAM (R‐BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma

Martin D. Berger(University of Bern), Thomas Pabst(University Hospital of Bern), Urban Novak(University of Bern), Giacomo Branger(University Hospital of Bern), Behrouz Mansouri Taleghani(University of Bern), Beatrice U. Mueller, Yara Banz(Beth Israel Deaconess Medical Center), Bernd Klaeser(University Hospital of Bern)

Hematological Oncology

February 17, 2015

10.1002/hon.2197

Cited by 17

Related Papers

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

|Journal of Clinical Oncology|2004|300

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

|Blood|2010|189

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

|Journal of Clinical Oncology|2018|152

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

|The Lancet|2024|135

Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion

|Archives of Gynecology and Obstetrics|2019|96